Boothbay Fund Management’s Dianthus Therapeutics DNTH Stock Holding History

Boothbay Fund Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$723K	Buy	+7,420	New	+$648K	0.01%	1287
2025 Q4	–	Sell	-138,963	Closed	-$5.47M	–	2052
2025 Q3	$5.47M	Buy	+138,963	New	+$3.55M	0.08%	297
2021 Q4	–	Sell	-1,392	Closed	-$162K	–	1928
2021 Q3	$162K	Buy	1,392 +646	+87%	+$75.3K	﹤0.01%	1645
2021 Q2	$117K	Buy	+746	New	+$137K	﹤0.01%	1711
2021 Q1	–	Sell	-978	Closed	-$123K	–	1605
2020 Q4	$123K	Buy	+978	New	+$111K	﹤0.01%	1167
2019 Q3	–	Sell	-1,290	Closed	-$304K	–	796
2019 Q2	$304K	Buy	+1,290	New	+$319K	0.03%	529

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Boothbay Fund Management's DNTH Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 7,420 shares worth $723K. The stake represents 0.01% of the portfolio and ranks #1287 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in DNTH as recently as Q3 2025.

Boothbay Fund Management first reported a position in DNTH in Q2 2019 and has held it in 6 quarters since. The position peaked at $5.47M in Q3 2025. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Boothbay Fund Management held 7,420 shares of Dianthus Therapeutics worth $723K as of Q2 2026.
Dianthus Therapeutics was a new Boothbay Fund Management position in Q2 2026.
Dianthus Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1287 holding.
Boothbay Fund Management first reported a position in Dianthus Therapeutics in Q2 2019 and has held it in 6 quarters since.
Boothbay Fund Management's Dianthus Therapeutics position peaked at $5.47M in Q3 2025.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.